Switzerland

Gilead Sciences Switzerland Sàrl

General-Guisan-Strasse 8
6300 Zug
Switzerland

Phone: 41 (0)41 580 02 00 41 (0)41 580 02 00

Fax: 41 (0)41 580 02 98

Gilead Sciences is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead’s office in Zug is responsible for medical, sales and marketing activities for our products in Switzerland.

Read more about Transparency Reporting

Relationships with Patient Organizations and NGOs

Gilead provided support to the following patient organizations and NGOs in 2020. The information is correct at the time of writing (May 2021). The information is subject to change and periodic updates. For a listing of previous years’ payments, click here.

Patient Organisation and NGO Description of Activity Amount Funded CHF
Aids Hilfe Bern HIV Peer 2 Peer Projekt AIDS Hilfe Bern 2019 - 2021 7500
Aids-Hilfe Schweiz Urgent Action Plan Corona 15000
Aids-Hilfe Schweiz Herbst Awareness & Test Campaign 2020 7500
Aids-Hilfe Schweiz Big HIV Awareness and Testing Campaign Fall 2020 60000
Association Ose Thérapies OSE Therapies Grant 5000
Fachstelle Für Sexuelle Gesundheit Zürich Segz Checkpoint in discussion 32500
Fachstelle Für Sexuelle Gesundheit Zürich Segz Checkpoint Mobile Testing 2019 20000
Fachstelle Für Sexuelle Gesundheit Zürich Segz Mobile testing for migrants 8800
Fachstelle Für Sexuelle Gesundheit Zürich Segz Checkpoint Mobile Testing 2020 20000
Hopos-Dachverband Projekt HOPOS 2020-2021 10000
Krebsliga Graubünden Kolorektal-Karzinom Screening Programm CME 2020 2000
Life4me.Plus To Fight Aids, Hepatitis C And Tuberculosis German HIV news service 2020 7000
Life4me.Plus To Fight Aids, Hepatitis C And Tuberculosis German HIV news service 2020 7000
Positivrat Schweiz Grant Positivrat activities 2020 20000
Swiss Hepa - Schweizer Leberpatienten Verein Swiss HePa 2019 activities 8000
Swiss Hepa - Schweizer Leberpatienten Verein Yearly Sponsoring 2020 10000

Publication of Clinical Study Results 

As of 2020, Gilead discloses clinical study results of newly authorized products in Switzerland by Swissmedic according to the requirements laid out in Art. 71-73 TPO (Ordinance on Therapeutic Products).

Products are listed in alphabetical order.

Product 

Active Substance

Authorization Number

Date of Authorization

Tecartus®

Autologous anti-CD19-transduced
CD3+ cells

67884

25.08.2021

Trodelvy®

Sacituzumab govitecan

68179

09.09.2021

Veklury®

Remdesivir

68026 / 68043

25.11.2020

This page is intended for visitors outside of the United States.